StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
59
This month
1
This year
8
Publishing Date
2024 - 04 - 12
1
2024 - 03 - 06
1
2024 - 02 - 22
1
2024 - 02 - 21
1
2024 - 02 - 15
1
2024 - 01 - 08
1
2024 - 01 - 04
1
2024 - 01 - 02
1
2023 - 10 - 24
1
2023 - 10 - 11
1
2023 - 10 - 04
1
2023 - 08 - 08
1
2023 - 05 - 11
1
2023 - 04 - 26
1
2023 - 04 - 25
1
2023 - 04 - 11
1
2023 - 03 - 24
1
2023 - 03 - 22
1
2023 - 02 - 09
1
2023 - 01 - 30
1
2023 - 01 - 03
1
2022 - 12 - 16
1
2022 - 10 - 28
2
2022 - 10 - 20
1
2022 - 09 - 07
1
2022 - 08 - 29
1
2022 - 08 - 04
1
2022 - 08 - 03
1
2022 - 07 - 27
1
2022 - 05 - 25
1
2022 - 05 - 16
1
2022 - 05 - 12
1
2022 - 05 - 11
1
2022 - 04 - 20
1
2022 - 03 - 08
1
2022 - 02 - 17
1
2022 - 02 - 15
1
2022 - 01 - 24
1
2022 - 01 - 11
1
2021 - 11 - 04
1
2021 - 10 - 28
1
2021 - 10 - 11
1
2021 - 09 - 23
1
2021 - 09 - 16
1
2021 - 09 - 15
1
2021 - 09 - 10
1
2021 - 09 - 01
1
2021 - 08 - 13
1
2021 - 08 - 09
1
2021 - 07 - 20
1
2021 - 06 - 25
1
2021 - 06 - 24
1
2021 - 06 - 08
1
2021 - 05 - 24
1
2021 - 04 - 27
1
2021 - 04 - 20
1
2021 - 04 - 01
1
2021 - 03 - 17
1
Sector
Communications
2
Finance
3
Health technology
59
Manufacturing
2
N/a
1
Professional, scientific, and technical services
1
Tags
100
1
Abbv-951
1
Abbvie
10
Aesthetic
2
Air
1
Alliances
1
Als
1
Application
2
Atopic dermatitis
1
Awards
1
Biomidwest
6
Biotech-bay
1
Biotech-beach
2
Bla submission
1
Blood
1
Botox
1
Breast cancer
1
Cancer
2
Cd20
3
Children
1
Clinical-trials-phase-iii
4
Collaboration
2
Conference
4
Contraceptive
1
Derm
3
Dermatitis
2
Designation
1
Disease
5
Drug
4
Duobody
3
Earnings
5
Ema
2
Events
4
Eye
2
Fda
5
Financial
3
Genetown
2
Global
2
Grant
2
Growth
2
Ironwood
2
Linzess
4
Market
3
N/a
28
Parkinson
2
People
3
Pharmaceuticals
3
Phase 3
4
Positive
2
Program
2
Research
4
Results
7
Rinvoq
3
Sales
2
Skin
2
Therapeutics
3
Treatment
8
Trial
2
Ulcerative colitis
2
Year
3
Entities
Abbott laboratories
1
Abbvie inc.
59
Alkermes plc
1
Amgen inc.
1
Anika therapeutics inc.
1
Astellas pharma inc
1
Astrazeneca plc
1
Bausch health companies inc.
1
Cerevel therapeutics holdings, inc.
1
Coherus biosciences, inc.
3
Csl ltd
1
Cytodyn inc.
1
Enanta pharmaceuticals, inc.
1
Endo international plc
1
Genmab a/s
4
Glaxosmithkline plc
2
I-mab
1
Ironwood pharmaceuticals, inc.
4
Johnson & johnson
1
Mallinckrodt plc
1
Morgan stanley
2
Neurocrine biosciences, inc.
1
Novartis ag
2
Novo nordisk a/s
1
Orange
2
Sanofi
3
Summit therapeutics inc.
1
Teva pharmaceutical industries ltd
3
Ucb s.a.
1
Vectivbio holding ag
1
Viatris inc.
1
Xencor, inc.
1
Symbols
AAPL
60
ABB
42
ABBV
59
ABT
60
ALB
37
ALNY
41
ARVL
218
BHC
37
BKI
129
BLDP
41
BLK
37
BMO
44
BMRN
39
BMY
67
CCLD
41
CNDT
79
CSCO
51
CYBN
49
DCT
52
ERIC
110
EXPR
37
EXTR
67
F
43
FAT
37
FCN
39
FNCTF
463
GE
41
GILD
44
HON
47
IBM
41
INTC
66
IT
55
JAGX
78
JNJ
267
LLY
100
LPLA
95
LTUM
58
MMM
43
MRNA
51
MS
266
MSFT
63
NVO
37
OMQS
48
ORCL
66
PFE
45
PPRUF
62
PPRUY
62
SAP
53
SAPGF
46
SNY
268
SNYNF
218
STIM
39
STM
40
STMEF
40
TMO
71
TRU
50
TWST
51
VZ
120
WEX
64
XYF
72
Exchanges
Nasdaq
21
Nyse
59
Crawled Date
2024 - 04 - 12
1
2024 - 03 - 06
1
2024 - 02 - 22
1
2024 - 02 - 21
1
2024 - 02 - 15
1
2024 - 01 - 08
1
2024 - 01 - 04
1
2024 - 01 - 02
1
2023 - 10 - 24
1
2023 - 10 - 11
1
2023 - 10 - 04
1
2023 - 08 - 08
1
2023 - 05 - 11
1
2023 - 04 - 26
1
2023 - 04 - 25
1
2023 - 04 - 11
1
2023 - 03 - 24
1
2023 - 03 - 22
1
2023 - 02 - 09
1
2023 - 01 - 30
1
2023 - 01 - 03
1
2022 - 12 - 16
1
2022 - 10 - 28
2
2022 - 10 - 20
1
2022 - 09 - 07
1
2022 - 08 - 29
1
2022 - 08 - 04
1
2022 - 08 - 03
1
2022 - 07 - 27
1
2022 - 05 - 25
1
2022 - 05 - 16
1
2022 - 05 - 12
1
2022 - 05 - 11
1
2022 - 04 - 20
1
2022 - 03 - 08
1
2022 - 02 - 17
1
2022 - 02 - 15
1
2022 - 01 - 24
1
2022 - 01 - 11
1
2021 - 11 - 04
1
2021 - 10 - 28
1
2021 - 10 - 11
1
2021 - 09 - 23
1
2021 - 09 - 16
1
2021 - 09 - 15
1
2021 - 09 - 10
1
2021 - 09 - 01
1
2021 - 08 - 13
1
2021 - 08 - 09
1
2021 - 07 - 20
1
2021 - 06 - 25
1
2021 - 06 - 24
1
2021 - 06 - 08
1
2021 - 05 - 24
1
2021 - 04 - 27
1
2021 - 04 - 20
1
2021 - 04 - 01
1
2021 - 03 - 17
1
Crawled Time
00:00
41
00:20
6
01:00
32
01:10
1
02:00
23
03:00
24
04:00
18
04:20
7
05:00
12
06:00
20
07:00
25
08:00
24
08:20
1
09:00
23
10:00
16
10:10
1
10:51
1
11:00
42
12:00
58
12:15
10
12:20
15
12:30
6
12:34
1
13:00
59
13:07
3
13:13
1
13:15
10
13:17
1
13:20
12
13:27
1
13:30
17
13:50
1
14:00
52
14:03
1
14:04
1
14:07
1
14:12
1
14:15
7
14:20
10
14:30
12
15:00
50
15:11
1
15:15
7
15:20
10
15:30
16
15:49
1
16:00
49
16:20
7
17:00
38
17:37
1
17:43
1
18:00
39
18:04
1
18:31
2
19:00
32
20:00
49
20:20
7
21:00
27
22:00
37
23:00
45
Source
www.biospace.com
31
www.globenewswire.com
5
www.prnewswire.com
23
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
ABBV
crawled time :
13:00
save search
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published:
2024-04-12
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-0.66%
|
O:
-1.92%
H:
0.0%
C:
0.0%
qulipta
abbvie
treatment
for
migraine
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
Published:
2024-03-06
(Crawled : 13:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-6.64%
|
O:
0.09%
H:
2.11%
C:
1.49%
abbvie
meeting
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
Published:
2024-02-22
(Crawled : 13:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-5.63%
|
O:
-0.88%
H:
1.46%
C:
1.13%
abbvie
collaboration
immunology
BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs
Published:
2024-02-21
(Crawled : 13:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-5.86%
|
O:
-0.25%
H:
0.0%
C:
0.0%
botox
women
grant
program
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
Published:
2024-02-15
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
-3.91%
|
O:
0.48%
H:
1.56%
C:
1.48%
IRWD
|
$7.94
4.47%
4.28%
2.5M
|
Health Technology
|
-48.74%
|
O:
-5.63%
H:
7.34%
C:
2.81%
year
pharmaceuticals
ironwood
financial
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Published:
2024-01-08
(Crawled : 13:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
3.03%
|
O:
0.52%
H:
0.0%
C:
0.0%
positive
program
trial
results
AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
Published:
2024-01-04
(Crawled : 13:00)
- prnewswire.com
GNMSF
|
$290.38
3.83%
220
|
Health Technology
|
-9.55%
|
O:
0.16%
H:
1.95%
C:
1.94%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
3.27%
|
O:
-0.34%
H:
0.0%
C:
0.0%
GMAB
|
$28.72
1.38%
1.36%
360K
|
Health Technology
|
-7.89%
|
O:
1.25%
H:
0.99%
C:
0.63%
conference
abbvie
AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published:
2024-01-02
(Crawled : 13:00)
- prnewswire.com
GNMSF
|
$290.38
3.83%
220
|
Health Technology
|
-9.87%
|
O:
-0.78%
H:
4.49%
C:
1.55%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
7.33%
|
O:
-0.09%
H:
3.38%
C:
3.18%
GMAB
|
$28.72
1.38%
1.36%
360K
|
Health Technology
|
-9.86%
|
O:
-1.54%
H:
3.6%
C:
2.42%
CERE
|
$42.15
0.02%
0.02%
810K
|
Finance
|
-0.45%
|
O:
-0.14%
H:
0.19%
C:
-0.31%
conference
abbvie
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
Published:
2023-10-24
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
14.98%
|
O:
0.3%
H:
0.0%
C:
0.0%
positive
treatment
topline
results
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Published:
2023-10-11
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
11.39%
|
O:
-0.08%
H:
0.0%
C:
0.0%
abbvie
dermatitis
rinvoq
AbbVie to Host Third-Quarter 2023 Earnings Conference Call
Published:
2023-10-04
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
12.58%
|
O:
-0.89%
H:
0.0%
C:
0.0%
conference
abbvie
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
Published:
2023-08-08
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
10.7%
|
O:
0.33%
H:
0.0%
C:
0.0%
IRWD
|
$7.94
4.47%
4.28%
2.5M
|
Health Technology
|
-30.22%
|
O:
-3.96%
H:
0.0%
C:
-5.41%
linzess
sales
year
pharmaceuticals
ironwood
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
Published:
2023-05-11
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
13.65%
|
O:
0.59%
H:
0.19%
C:
-0.48%
SMMT
A
|
$3.51
0.0%
1.7M
|
Health Technology
|
65.09%
|
O:
0.47%
H:
0.47%
C:
-9.62%
therapeutics
financial
results
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Published:
2023-04-26
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
0.92%
|
O:
-1.35%
H:
0.36%
C:
-0.54%
XNCR
|
$18.385
-2.98%
-3.07%
830K
|
Health Technology
|
-34.54%
|
O:
-0.5%
H:
0.82%
C:
-3.72%
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
Published:
2023-04-25
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
1.42%
|
O:
0.44%
H:
0.84%
C:
0.05%
ENTA
|
$13.28
0.38%
0.38%
140K
|
Health Technology
|
-63.38%
|
O:
1.32%
H:
0.0%
C:
-5.7%
mavyret
life
royalties
pharmaceuticals
sciences
global
Hyaluronic acid market size to grow by USD 3,719.76 million between 2022 and 2027, Growth driven by the huge requirement for safe and stable drugs that require minimal monitoring - Technavio
Published:
2023-04-11
(Crawled : 13:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-16.98%
|
O:
-1.75%
H:
0.0%
C:
0.0%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
3.18%
|
O:
0.13%
H:
0.68%
C:
-0.07%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-16.49%
|
O:
0.4%
H:
0.0%
C:
0.0%
ANIK
|
$25.84
1.61%
1.59%
49K
|
Health Technology
|
-8.69%
|
O:
-3.52%
H:
4.28%
C:
1.38%
growth
market
AbbVie Clinches Back-to-Back Clinical Wins in Ulcerative Colitis, Lupus
Published:
2023-03-24
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
7.15%
|
O:
-0.01%
H:
2.06%
C:
1.76%
abbvie
lupus
ulcerative colitis
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
Published:
2023-03-22
(Crawled : 13:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
6.15%
|
O:
-0.7%
H:
0.77%
C:
-1.29%
abbv-951
drug
abbvie
update
application
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
Published:
2023-02-09
(Crawled : 13:00)
- biospace.com/
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
15.08%
|
O:
2.69%
H:
3.5%
C:
0.13%
abbvie
financial
results
Emergency contraceptive pills market to grow by 3.72% Y-O-Y from 2022 to 2023: Rise in the number of initiatives to create awareness will drive growth -Technavio
Published:
2023-01-30
(Crawled : 13:00)
- prnewswire.com
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
13.76%
|
O:
-0.28%
H:
0.86%
C:
-0.15%
contraceptive
growth
market
← Previous
1
2
3
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.